NeoCura Bio Awarded 'Most Innovative Company of the Year' for AI-Powered mRNA Cancer Vaccines

On April 1, 2026, the "Nucleic Acid Summit 2026: The 5th China Nucleic Acid Drugs and Novel Vaccines Industry Conference," organized by Tansi Bio, opened in Shanghai. The conference focuses on the cutting-edge advancements in nucleic acid drug research and development strategies for novel vaccines, with in-depth discussions on key industrialization topics such as delivery systems and large-scale production, aiming to accelerate the clinical translation of innovative achievements.

During the conference, the "2026 China Nucleic Acid Drugs and New Vaccine Industry Star" award was announced.NeoCura has successfully won the "Most Innovative Award of the Year" for its original technical capabilities and clinical development progress in the field of mRNA personalized cancer vaccines.

This award, through a multi-layered review process and rigorous selection, fully reflects its professionalism and authority. NeoCura's triumph this time marks the industry's full recognition of its leading position as a research and development leader in the "AI + RNA" field, and is also an accolade for its commitment to solving unmet clinical needs through cutting-edge technology.

In the vast ocean of biomedicine, nucleic acid drugs and vaccines are hailed as the "twin stars" of next-generation therapies. Among them, mRNA tumor neoantigen vaccines represent one of the most captivating exploration directions in this field. The core challenge lies in precisely screening out neoantigens capable of effectively stimulating T-cell anti-tumor immune responses from the massive number of mutations produced by patient tumor cells. Traditional methods are akin to finding a needle in a haystack. NeoCura has provided an innovative solution to this problem through the deep integration of artificial intelligence (AI).

NeoCura's self-developedNeoCura AI ALPINE Tumor Neoantigen Prediction System, by deeply integrating multi-omics and immune big data, has raised the prediction accuracy of neoantigens to an internationally advanced level, laying the foundation for the effectiveness of tumor neoantigen vaccines.Based on this platform, NeoCura has developedmRNA Personalized Tumor Neoantigen Vaccine XH001. This vaccine has received clinical trial approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration in China and is currently undergoing Phase I clinical research at Peking Union Medical College Hospital and Beijing Cancer Hospital for adjuvant treatment in postoperative patients with high-risk recurrent solid tumors.

This marks the successful transition of China's self-developed mRNA tumor neoantigen vaccine from preclinical research to clinical trials, representing a significant milestone in the development of innovative domestic drugs and offering a new option for personalized immunotherapy in cancer treatment.

Globally,Frequent breakthroughs have been reported in the field of mRNA tumor vaccines, and China's innovative forces, represented by NeoCura, are rapidly emerging. This evaluation is a testament to that."Annual Most Innovative Award", which is not only a recognition of the past, but also an expectation for the future. WithThe advancement of clinical research pipelines such as XH001 and the company's industrialization capabilitiesWith the continuous consolidation of strength, NeoCura is steadily becoming a driving force in the new era of precision immunotherapy for tumors.The Core Force to Crack the Code of Life and Illuminate the Dawn of Treatment。

More content click "Read Original" below